Graves Orbitopathy Pipeline, Clinical Trials, and Key Companies|Companies- Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical

June 09 13:16 2023
(United States, Nevada, Las Vegas), DelveInsight’s “Graves’ Orbitopathy- Pipeline Insight, 2023” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Graves’ Orbitopathy pipeline landscape.

(United States, Nevada, Las Vegas), DelveInsight’s “Graves’ Orbitopathy- Pipeline Insight, 2023” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Graves’ Orbitopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Graves Orbitopathy Pipeline Report

  • Over 8+ companies and 8+ pipeline drugs in Graves Orbitopathy are in various stages of development, and their anticipated acceptance in the Graves Orbitopathy market would significantly increase market revenue. 

  • Leading Graves Orbitopathy companies developing novel drug candidates to improve the Graves Orbitopathy treatment landscape include Astellas, Jiangsu Hengrui Medicine, Novartis, and others

  • Promising Graves Orbitopathy pipeline therapies in various stages of development include Linsitinib, SHR 1314, and many others.

Graves Orbitopathy Overview

Graves orbitopathy (Graves eye disease or Graves ophthalmopathy) is a constellation of signs and symptoms related to the orbit and surrounding tissues in patients with Graves disease. It can also sporadically occur in patients who are euthyroid or even hypothyroid as a result of chronic thyroiditis. It is an autoimmune process affecting retro-ocular tissues. In its severe form, it can be sight-threatening; thus, prompt evaluation and timely referral and management become of utmost importance. Graves orbitopathy occurs in patients with Graves disease and is an autoimmune disease of retro-ocular tissue. Complications can be severe and sight-threatening. It is important to know how to evaluate patients with Graves’ orbitopathy and treat them according to the severity of the disease. Graves orbitopathy has been said to occur in as many as 25 to 50% of patients diagnosed with Graves’ disease. 

Graves Orbitopathy Pipeline Analysis: Drug Profile

Linsitinib: Astellas

Linsitinib, which was in-licensed from Astellas Pharma to Sling Therapeutics, is designed to inhibit the insulin-like growth factor I receptor (IGF-1R). Dysfunction in the IGF-1R signaling pathway leads to a prevalence of thyroid-stimulating hormone receptor autoantibodies (TSHR-Abs) that drive excess fibrous tissue growth in TED. Independent data from a model of TED in patient fibroblast cells suggest that linsitinib is at least as potent as the currently available treatment. The U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for linsitinib for the treatment of TED. Currently, the drug is in the Phase II/III stage of Clinical trial evaluation for treating Graves Orbitopathy.

Discover more about the emerging Graves Orbitopathy  drugs @ Graves Orbitopathy Treatment Drugs

Graves Orbitopathy Pipeline Therapies and Key Companies

  • Linsitinib: Astellas

  • SHR 1314: Jiangsu Hengrui Medicine

And many others 

Graves Orbitopathy  Pipeline Therapeutics Assessment


DelveInsight’s Report covers around 33+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Route of Administration

Graves Orbitopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Scope of the Graves Orbitopathy Pipeline Report 

  • Coverage: Global 

  • Key Graves Orbitopathy  Companies: Astellas, Jiangsu Hengrui Medicine, Novartis, and others

  • Key Graves Orbitopathy Pipeline Therapies: Linsitinib, SHR 1314, and many others

  • Find out more about the Graves Orbitopathy  treatment options in development @ Graves Orbitopathy Clinical Trials

Table of Contents

1. Graves Orbitopathy Introduction

2. Graves Orbitopathy Executive Summary

3. Graves Orbitopathy Overview

4. Graves Orbitopathy Pipeline Therapeutics

5. Graves Orbitopathy Late-Stage Products (Phase III)

6. Graves Orbitopathy Mid-Stage Products (Phase  II)

7. Graves Orbitopathy Early Stage Products (Phase  I/II)

8. Graves Orbitopathy Preclinical Stage Products

9.  Graves Orbitopathy Discovery Stage Products

10. Graves Orbitopathy Therapeutic Assessment

11. Graves Orbitopathy Inactive Products

12. Graves Orbitopathy Collaborations Assessment- Licensing / Partnering / Funding

13. Graves Orbitopathy Unmet Needs

14. Graves OrbitopathyMarket Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

view more articles

About Article Author